AEGiS-13IAC: HAART in real life: Predictors of virologic failure in a cohort of 381 patients in Buenos Aires.

13th International AIDS Conference


Durban, South Africa - July 9-July 14, 2000

DonateNow
Print this article

HAART in real life: Predictors of virologic failure in a cohort of 381 patients in Buenos Aires.

Int Conf AIDS 2000 Jul 9-14; 13:(abstract no. WeOrB611)

Zala C, Sued O, Del Sol E, Tocci M, De la Iglesia G, Wekselman S, Abusamra L, Cahn P
C. Zala, Hospital Juan Fernandez, Angel Peluffo 3932 (1202), Buenos Aires, Argentina, Tel.: +54 11 4981 7777, Fax: +54 11 4982 4024, E-mail: pcahn@huesped.org.ar

OBJECTIVE: To describe factors associated with virologic failure in clinical practice in a reference center in Buenos Aires.

METHODS: Chart review from patients started in a triple drug regimen during 1998-99.Eligible pts were those with at least 6 months of follow up and baseline and postreatment determinations of viral load (VL) and CD4 counts were included. The following variables were included in an univariate and multavariate analysis: Gender, being naive or experienced CD4 & VL (baseline and post-treatment), previous AIDS at entry, use of NNRTI's, PI's, Adverse events. Failure was defined as VL> 500 copies after at least 6 months of HAART.

RESULTS: A total of 381 pts were included: 281 male, 91 female, 125 (32.8%) had prior AIDS, 180 (47.2%) naive, 142 (37.3%) were on their 2nd regime and 59 (15.5%) had 3 or more treatments. NNRTI's (+ 2NRTI) were prescribed to 67 pts(17.5%), PI- based therapy to 313 (82%), triple nuke to 1 case. No differences were found in regard to gender, the use of ZDV or d4T in the combination, nor comparing NNRTI's vs PI's. Starting HAART being naive, VL > 155,000 copies and CD4> 255 at baseline were the strongest predictors of viirologic success. AIDS prior to treatment initiation was associated with higher failures rates.

CONCLUSIONS: In our series, we confirm that patients on HAART are more likely to respond if they are initiated before the onset of AIDS, with relatively preserved CD4 counts and viral loads. PI and NNRTI-based regimes showed no difference in this study.

Keywords: AEGIS, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Viral Load, Acquired Immunodeficiency Syndrome, Female, Male, Human, virologyKWDaegis,antiretroviraltherapy,highlyactive,cd4lymphocytecount,viralload,acquiredimmunodeficiencysyndrome,female,male,human,virology
000709
WeOrB611

Copyright © 2000 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.